Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tecadenoson + esmolol
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Tecadenoson + esmolol is a **combination of two intravenous agents** investigated for rate control in patients with atrial fibrillation. **Tecadenoson** is a selective A1-adenosine receptor agonist that induces AV nodal conduction delay, thus slowing the ventricular response in atrial fibrillation. **Esmolol** is a short-acting, cardioselective beta-1 adrenergic receptor antagonist (beta-blocker) that reduces heart rate by antagonizing sympathetic input to the AV node. This combination has been studied for enhanced rate control, specifically for acute treatment of atrial fibrillation, and has been shown to synergistically reduce heart rate, with greater efficacy in reducing ventricular rate variability and response than either agent alone. No unique marketed product under this combination exists; development has primarily been as an investigational therapeutic approach in controlled clinical trials[1][2][3][4].
- Brand names
- esmolol (often marketed as Brevibloc, but for this combination, no unique brand)
- Other names
- tecadenoson + esmolol
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADRB1 (β1)
Beyond the preview
Go deeper on tecadenoson + esmolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tecadenoson + esmolol.